{"gene":"RNASEH2B","run_date":"2026-06-10T06:43:37","timeline":{"discoveries":[{"year":2008,"finding":"RNASEH2B is a non-catalytic accessory subunit of the heterotrimeric human RNase H2 complex. It contains a PIP-box motif that confers PCNA binding to the RNase H2 holoenzyme. RNASEH2B and RNASEH2C form a soluble B/C sub-complex that acts as a nucleation site for RNASEH2A recruitment to form the active trimer. Of five AGS-associated mutations in RNASEH2B and RNASEH2C tested, none in RNASEH2B showed significant reduction in catalytic activity, indicating RNASEH2B mutations cause disease through mechanisms other than direct loss of enzymatic activity.","method":"Biochemical reconstitution of human RNase H2 complex, in vitro enzymatic activity assays, PCNA binding assays, analysis of AGS-linked mutant proteins","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution, enzymatic assays, mutagenesis, and PCNA binding assays in a single rigorous study with multiple orthogonal methods","pmids":["19015152"],"is_preprint":false},{"year":2022,"finding":"Loss of RNASEH2B impairs ribonucleotide excision repair (RER) and sensitizes prostate cancer cells to PARP inhibition via PARP trapping. Co-deletion of RB1 (co-located at chromosome 13q14) overcomes this sensitivity through E2F1-induced upregulation of BRCA2 expression, enhancing homologous recombination repair capacity. Additional BRCA2 loss resensitizes RNASEH2B/RB1 co-deleted cells to PARP inhibition. ATR inhibition can disrupt E2F1-induced BRCA2 expression and overcome PARP inhibitor resistance caused by RB1 loss.","method":"Cancer cell line loss-of-function experiments, PARP inhibitor sensitivity assays, genetic epistasis (RB1/BRCA2 co-deletion models), E2F1 pathway manipulation, ATR inhibitor rescue experiments","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal genetic epistasis experiments with defined phenotypic readouts and mechanistic pathway placement in a single rigorous study","pmids":["35179959"],"is_preprint":false},{"year":2022,"finding":"In RNASEH2B-mutated patient-derived lymphoblastoid cell lines, mitochondrial morphological alterations were observed, ROS production and 8-oxoGuanine levels were increased, VDAC1 signal was elevated (suggesting mitochondrial pore formation), and elevated cytoplasmic mtDNA levels were detected compared to controls, implicating mitochondrial dysfunction and mtDNA release in AGS pathogenesis.","method":"Transmission electron microscopy, flow cytometry (ROS, mitochondrial membrane potential), Seahorse metabolic analyzer, immunofluorescence (8-oxoGuanine, VDAC1), Western blot and RT-qPCR for mtDNA release — patient LCLs vs. controls","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — multiple orthogonal methods in patient-derived cells, single lab, no genetic rescue or reconstitution to confirm RNASEH2B as direct cause","pmids":["36430958"],"is_preprint":false},{"year":2023,"finding":"An intronic RNASEH2B variant (c.322-17 A>G) affects pre-mRNA splicing, causing 16-nucleotide intronic retention in the RNASEH2B transcript, introduction of an out-of-frame early termination codon, and reduced RNASEH2B protein expression in patient blood.","method":"RNA studies (splice analysis), exome and genome sequencing, mRNA expression quantification","journal":"European journal of medical genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct RNA splicing assay with functional consequence (reduced protein), single case/lab","pmids":["36775013"],"is_preprint":false},{"year":2021,"finding":"Novel compound heterozygous mutations in RNASEH2B reduce RNase H2B transcript and protein levels; structural analysis showed both mutations remove intramolecular contacts, destabilizing the RNase H2B subunit and the entire RNase H2 complex. Lower RNase H2A and deep depletion of RNase H2C protein levels were also observed in the affected patient, indicating interdependence of complex subunit stability.","method":"NGS sequencing, Western blot (protein quantification), RT-qPCR (transcript quantification), structural/computational modeling","journal":"Frontiers in immunology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — protein/transcript quantification in patient cells plus computational structural modeling; no in vitro reconstitution or mutagenesis to validate structural predictions","pmids":["33981319"],"is_preprint":false},{"year":2025,"finding":"An intronic RNASEH2B variant (c.65-13G>A) creates a new splice site, leading to an 11-bp extension in exon 2, causing a frameshift (p.Glu22Valfs*7) and truncation of the RNASEH2B protein.","method":"RNA analysis of splice site usage, next-generation sequencing","journal":"Annals of clinical and laboratory science","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct RNA splicing assay demonstrating molecular mechanism of variant pathogenicity, single case","pmids":["40750230"],"is_preprint":false},{"year":2024,"finding":"Inducible overexpression of RNASEH2B increases levels of the active RNase H2 heterotrimer, demonstrating RNASEH2B as a rate-limiting subunit for assembly of the active complex. Despite increased heterotrimer levels, RNASEH2B overexpression is paradoxically associated with increased RNA:DNA hybrid levels under basal conditions, yet prevents further increases in RNA:DNA hybrids and reduces replication fork stalling caused by camptothecin or hydroxyurea. In the presence of oncogenic HRAS, increased RNase H2 levels limit RAS-induced replication fork stalling and cell death.","method":"Inducible overexpression system, RNA:DNA hybrid immunofluorescence (S9.6 antibody), DNA fiber assay (replication fork stalling), gene expression profiling, oncogene-induced replication stress models","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — multiple orthogonal methods in a single preprint study, not yet peer-reviewed","pmids":["bio_10.1101_2024.12.16.628316"],"is_preprint":true}],"current_model":"RNASEH2B is a non-catalytic accessory subunit of the heterotrimeric RNase H2 endoribonuclease that, together with RNASEH2C, forms a B/C sub-complex serving as a nucleation site for RNASEH2A to assemble the active enzyme; its PIP-box mediates PCNA binding to recruit the complex to replication forks for ribonucleotide excision repair (RER), and its loss impairs RER, traps PARP at DNA lesions to sensitize cells to PARP inhibition, promotes replication stress, and triggers innate immune activation through accumulation of nucleic acid intermediates and mitochondrial mtDNA release."},"narrative":{"mechanistic_narrative":"RNASEH2B is the non-catalytic accessory subunit of the heterotrimeric human RNase H2 endoribonuclease, functioning in ribonucleotide excision repair (RER) at sites of replication [PMID:19015152, PMID:35179959]. It nucleates assembly of the active enzyme: RNASEH2B and RNASEH2C form a soluble B/C sub-complex that serves as the docking site for catalytic RNASEH2A, and its PIP-box motif confers PCNA binding to the holoenzyme [PMID:19015152]. RNASEH2B is rate-limiting for assembly of the active trimer, and the stability of the entire complex—including RNASEH2A and RNASEH2C protein levels—depends on intact RNASEH2B [PMID:33981319, PMID:bio_10.1101_2024.12.16.628316]. Functionally, loss of RNASEH2B impairs RER and sensitizes cells to PARP inhibition through PARP trapping, a vulnerability that can be reversed by co-deletion of the neighboring 13q14 gene RB1 via E2F1-driven BRCA2 upregulation and restored homologous recombination [PMID:35179959]. Increased RNase H2 levels restrain replication fork stalling caused by camptothecin, hydroxyurea, or oncogenic HRAS, linking the complex to replication stress tolerance [PMID:bio_10.1101_2024.12.16.628316]. RNASEH2B is a cause of Aicardi-Goutières syndrome; its disease-associated mutations act largely without abolishing catalytic activity, instead reducing protein expression and destabilizing the complex, and patient cells exhibit mitochondrial dysfunction and cytoplasmic mtDNA accumulation [PMID:19015152, PMID:36430958, PMID:33981319].","teleology":[{"year":2008,"claim":"Established RNASEH2B as a structural, non-catalytic subunit that nucleates RNase H2 assembly and recruits the complex to PCNA, and showed that AGS mutations do not act by abolishing enzymatic activity—reframing how these mutations cause disease.","evidence":"Biochemical reconstitution of the human RNase H2 trimer, in vitro activity assays, PCNA binding assays, and analysis of AGS-linked mutant proteins","pmids":["19015152"],"confidence":"High","gaps":["Did not define the non-enzymatic mechanism by which RNASEH2B mutations cause disease","PIP-box contribution to in vivo fork recruitment not quantified","No structure of the assembled trimer reported in this study"]},{"year":2021,"claim":"Connected patient RNASEH2B mutations to destabilization of the whole complex, showing subunit interdependence whereby loss of RNASEH2B lowers RNASEH2A and depletes RNASEH2C protein.","evidence":"NGS, Western blot and RT-qPCR quantification in patient cells with computational structural modeling of destabilizing mutations","pmids":["33981319"],"confidence":"Low","gaps":["Structural predictions not validated by in vitro reconstitution or mutagenesis","Single patient case","Functional RER consequence not directly measured"]},{"year":2022,"claim":"Placed RNASEH2B loss in a cancer therapeutic context, showing impaired RER sensitizes cells to PARP inhibition via PARP trapping and mapping a resistance mechanism through co-deleted RB1 and E2F1-driven BRCA2.","evidence":"Prostate cancer loss-of-function models, PARP inhibitor sensitivity assays, RB1/BRCA2 epistasis, and ATR inhibitor rescue experiments","pmids":["35179959"],"confidence":"High","gaps":["Generality across other tumor types not established","Direct biochemical link between RER intermediates and PARP trapping not resolved","In vivo therapeutic validation limited"]},{"year":2022,"claim":"Linked RNASEH2B mutation to mitochondrial dysfunction in AGS, with elevated ROS, 8-oxoGuanine, VDAC1, and cytoplasmic mtDNA implicating mtDNA release in disease pathogenesis.","evidence":"TEM, flow cytometry, Seahorse, immunofluorescence and mtDNA quantification in patient lymphoblastoid lines versus controls","pmids":["36430958"],"confidence":"Medium","gaps":["No genetic rescue or reconstitution to confirm RNASEH2B as direct cause","Causal chain from RER defect to mtDNA release not demonstrated","Single-lab, patient-cell observations"]},{"year":2023,"claim":"Defined a splicing mechanism of pathogenicity, showing an intronic variant causes intron retention, premature termination, and reduced RNASEH2B protein.","evidence":"Splice analysis, exome/genome sequencing, and mRNA expression quantification in patient blood","pmids":["36775013"],"confidence":"Medium","gaps":["Single case","Downstream effect on complex assembly not measured","No functional RER readout"]},{"year":2024,"claim":"Showed RNASEH2B is rate-limiting for active heterotrimer assembly and that increased RNase H2 levels limit replication fork stalling under genotoxic and oncogenic stress.","evidence":"Inducible overexpression, S9.6 RNA:DNA hybrid immunofluorescence, DNA fiber assays, and oncogene-induced replication stress models (preprint)","pmids":["bio_10.1101_2024.12.16.628316"],"confidence":"Medium","gaps":["Not yet peer-reviewed","Paradoxical basal increase in RNA:DNA hybrids upon overexpression unexplained","Mechanism of fork protection beyond hybrid resolution unclear"]},{"year":2025,"claim":"Extended the spectrum of splicing-based loss-of-function mechanisms, identifying a variant that creates a new splice site causing frameshift and protein truncation.","evidence":"RNA analysis of splice site usage and next-generation sequencing in a single case","pmids":["40750230"],"confidence":"Medium","gaps":["Single case","Effect on complex stability and RER not directly assessed","No cellular phenotype reported"]},{"year":null,"claim":"How RER failure mechanistically drives innate immune activation and mtDNA release in AGS, and whether the PARP-trapping vulnerability generalizes as a therapeutic strategy, remain open.","evidence":"","pmids":[],"confidence":"Medium","gaps":["Causal pathway from nucleic-acid intermediates to immune signaling not reconstituted","No structure of the AGS-mutant trimer linking destabilization to phenotype","Therapeutic generalizability beyond prostate cancer untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[0,6]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0]}],"localization":[],"pathway":[{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[0,1]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2]}],"complexes":["RNase H2"],"partners":["RNASEH2A","RNASEH2C","PCNA"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q5TBB1","full_name":"Ribonuclease H2 subunit B","aliases":["Aicardi-Goutieres syndrome 2 protein","AGS2","Deleted in lymphocytic leukemia 8","Ribonuclease HI subunit B"],"length_aa":312,"mass_kda":35.1,"function":"Non catalytic subunit of RNase H2, an endonuclease that specifically degrades the RNA of RNA:DNA hybrids. Participates in DNA replication, possibly by mediating the removal of lagging-strand Okazaki fragment RNA primers during DNA replication. Mediates the excision of single ribonucleotides from DNA:RNA duplexes","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q5TBB1/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/RNASEH2B","classification":"Not Classified","n_dependent_lines":60,"n_total_lines":1208,"dependency_fraction":0.04966887417218543},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"RNASEH2A","stoichiometry":10.0}],"url":"https://opencell.sf.czbiohub.org/search/RNASEH2B","total_profiled":1310},"omim":[{"mim_id":"615846","title":"AICARDI-GOUTIERES SYNDROME 7; AGS7","url":"https://www.omim.org/entry/615846"},{"mim_id":"615010","title":"AICARDI-GOUTIERES SYNDROME 6; AGS6","url":"https://www.omim.org/entry/615010"},{"mim_id":"610448","title":"CHILBLAIN LUPUS 1; CHBL1","url":"https://www.omim.org/entry/610448"},{"mim_id":"610330","title":"RIBONUCLEASE H2, SUBUNIT C; RNASEH2C","url":"https://www.omim.org/entry/610330"},{"mim_id":"610326","title":"RIBONUCLEASE H2, SUBUNIT B; RNASEH2B","url":"https://www.omim.org/entry/610326"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":123.4}],"url":"https://www.proteinatlas.org/search/RNASEH2B"},"hgnc":{"alias_symbol":["FLJ11712"],"prev_symbol":["DLEU8","AGS2"]},"alphafold":{"accession":"Q5TBB1","domains":[{"cath_id":"2.20.25.530","chopping":"15-92","consensus_level":"medium","plddt":88.1564,"start":15,"end":92},{"cath_id":"1.10.20.120","chopping":"161-188_205-237","consensus_level":"medium","plddt":86.3638,"start":161,"end":237},{"cath_id":"1.10.10","chopping":"93-159","consensus_level":"medium","plddt":85.5304,"start":93,"end":159}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q5TBB1","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q5TBB1-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q5TBB1-F1-predicted_aligned_error_v6.png","plddt_mean":76.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=RNASEH2B","jax_strain_url":"https://www.jax.org/strain/search?query=RNASEH2B"},"sequence":{"accession":"Q5TBB1","fasta_url":"https://rest.uniprot.org/uniprotkb/Q5TBB1.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q5TBB1/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q5TBB1"}},"corpus_meta":[{"pmid":"25604658","id":"PMC_25604658","title":"Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1.","date":"2015","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/25604658","citation_count":507,"is_preprint":false},{"pmid":"24183309","id":"PMC_24183309","title":"Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study.","date":"2013","source":"The Lancet. Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/24183309","citation_count":371,"is_preprint":false},{"pmid":"19015152","id":"PMC_19015152","title":"Contributions of the two accessory subunits, RNASEH2B and RNASEH2C, to the activity and properties of the human RNase H2 complex.","date":"2008","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/19015152","citation_count":112,"is_preprint":false},{"pmid":"25243380","id":"PMC_25243380","title":"Mutations in ADAR1, IFIH1, and RNASEH2B presenting as spastic paraplegia.","date":"2014","source":"Neuropediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/25243380","citation_count":72,"is_preprint":false},{"pmid":"35179959","id":"PMC_35179959","title":"RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer.","date":"2022","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/35179959","citation_count":38,"is_preprint":false},{"pmid":"33482855","id":"PMC_33482855","title":"Systemic inflammation and chronic kidney disease in a patient due to the RNASEH2B defect.","date":"2021","source":"Pediatric rheumatology online journal","url":"https://pubmed.ncbi.nlm.nih.gov/33482855","citation_count":23,"is_preprint":false},{"pmid":"29030706","id":"PMC_29030706","title":"Rare ADAR and RNASEH2B variants and a type I interferon signature in glioma and prostate carcinoma risk and tumorigenesis.","date":"2017","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/29030706","citation_count":17,"is_preprint":false},{"pmid":"33872687","id":"PMC_33872687","title":"Collapsing Glomerulopathy as a Complication of Type I Interferon-Mediated Glomerulopathy in a Patient With RNASEH2B-Related Aicardi-Goutières Syndrome.","date":"2021","source":"American journal of kidney diseases : the official journal of the National Kidney Foundation","url":"https://pubmed.ncbi.nlm.nih.gov/33872687","citation_count":15,"is_preprint":false},{"pmid":"36430958","id":"PMC_36430958","title":"Characterization of Mitochondrial Alterations in Aicardi-Goutières Patients Mutated in RNASEH2A and RNASEH2B Genes.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36430958","citation_count":10,"is_preprint":false},{"pmid":"31678772","id":"PMC_31678772","title":"Establishment of three iPSC lines from fibroblasts of a patient with Aicardi Goutières syndrome mutated in RNaseH2B.","date":"2019","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/31678772","citation_count":10,"is_preprint":false},{"pmid":"7586080","id":"PMC_7586080","title":"Synthesis and opioid activities of [D-Leu-8]Dynorphin(1-8) analogs containing a reduced peptide bond, psi(CH2-NH).","date":"1995","source":"Chemical & pharmaceutical bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/7586080","citation_count":10,"is_preprint":false},{"pmid":"38833311","id":"PMC_38833311","title":"RNASEH2B loss and PARP inhibition in advanced prostate cancer.","date":"2024","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/38833311","citation_count":8,"is_preprint":false},{"pmid":"22882256","id":"PMC_22882256","title":"A novel RNASEH2B splice site mutation responsible for Aicardi-Goutieres syndrome in the Faroe Islands.","date":"2012","source":"Acta paediatrica (Oslo, Norway : 1992)","url":"https://pubmed.ncbi.nlm.nih.gov/22882256","citation_count":6,"is_preprint":false},{"pmid":"34042169","id":"PMC_34042169","title":"[Aicardi-Goutieres syndrome: a family case due to alteration of the RNASEH2B gene].","date":"2021","source":"Revista de neurologia","url":"https://pubmed.ncbi.nlm.nih.gov/34042169","citation_count":4,"is_preprint":false},{"pmid":"33981319","id":"PMC_33981319","title":"Case Report: Novel Compound Heterozygous RNASEH2B Mutations Cause Aicardi-Goutières Syndrome.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33981319","citation_count":3,"is_preprint":false},{"pmid":"39890436","id":"PMC_39890436","title":"The c.529G>A (p.Ala177Thr) RNASEH2B Gene Pathogenic Variant as a First-Line Genetic Test for Aicardi-Goutières Syndrome: A Case Series of Four Moroccan Families.","date":"2025","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/39890436","citation_count":2,"is_preprint":false},{"pmid":"1980641","id":"PMC_1980641","title":"Synthesis and biological activity of [MeTyr1,MeArg7,D-Leu8]-dynorphin A(1-9)-NHEt and [D-Cys2-Cys5,MeArg7,D-Leu8]-dynorphin A(1-9)-NH2.","date":"1990","source":"Chemical & pharmaceutical bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/1980641","citation_count":2,"is_preprint":false},{"pmid":"36775013","id":"PMC_36775013","title":"Molecular characterization of an intronic RNASEH2B variant in a patient with Aicardi-Goutières syndrome.","date":"2023","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36775013","citation_count":1,"is_preprint":false},{"pmid":"26860721","id":"PMC_26860721","title":"[Phenotypic variations in Aicardi-Goutieres syndrome caused by RNASEH2B gene mutations: report of two new cases].","date":"2016","source":"Revista de neurologia","url":"https://pubmed.ncbi.nlm.nih.gov/26860721","citation_count":1,"is_preprint":false},{"pmid":"42158309","id":"PMC_42158309","title":"Expanding the phenotypic spectrum of RNASEH2B mutations: A new case of pure hereditary spastic paraplegia and a systematic review.","date":"2025","source":"Current journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/42158309","citation_count":0,"is_preprint":false},{"pmid":"41116827","id":"PMC_41116827","title":"[Aicardi-Goutières syndrome with atypical presentation: RNASEH2B gene mutation in an infant without microcephaly or intracranial calcifications (a case report)].","date":"2025","source":"The Pan African medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/41116827","citation_count":0,"is_preprint":false},{"pmid":"40750230","id":"PMC_40750230","title":"Recurrent Hemorrhagic Stroke and Microcephaly in a Newborn with Aicardi-Goutières Syndrome Caused by a Homozygous Intronic RNASEH2B Variant.","date":"2025","source":"Annals of clinical and laboratory science","url":"https://pubmed.ncbi.nlm.nih.gov/40750230","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.12.16.628316","title":"Human RNase H2 upregulation counteracts oncogene- and chemotherapy-induced replication stress","date":"2024-12-16","source":"bioRxiv","url":"https://doi.org/10.1101/2024.12.16.628316","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":14284,"output_tokens":2084,"usd":0.037056,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":9094,"output_tokens":2810,"usd":0.05786,"stage2_stop_reason":"end_turn"},"total_usd":0.094916,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2008,\n      \"finding\": \"RNASEH2B is a non-catalytic accessory subunit of the heterotrimeric human RNase H2 complex. It contains a PIP-box motif that confers PCNA binding to the RNase H2 holoenzyme. RNASEH2B and RNASEH2C form a soluble B/C sub-complex that acts as a nucleation site for RNASEH2A recruitment to form the active trimer. Of five AGS-associated mutations in RNASEH2B and RNASEH2C tested, none in RNASEH2B showed significant reduction in catalytic activity, indicating RNASEH2B mutations cause disease through mechanisms other than direct loss of enzymatic activity.\",\n      \"method\": \"Biochemical reconstitution of human RNase H2 complex, in vitro enzymatic activity assays, PCNA binding assays, analysis of AGS-linked mutant proteins\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution, enzymatic assays, mutagenesis, and PCNA binding assays in a single rigorous study with multiple orthogonal methods\",\n      \"pmids\": [\"19015152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Loss of RNASEH2B impairs ribonucleotide excision repair (RER) and sensitizes prostate cancer cells to PARP inhibition via PARP trapping. Co-deletion of RB1 (co-located at chromosome 13q14) overcomes this sensitivity through E2F1-induced upregulation of BRCA2 expression, enhancing homologous recombination repair capacity. Additional BRCA2 loss resensitizes RNASEH2B/RB1 co-deleted cells to PARP inhibition. ATR inhibition can disrupt E2F1-induced BRCA2 expression and overcome PARP inhibitor resistance caused by RB1 loss.\",\n      \"method\": \"Cancer cell line loss-of-function experiments, PARP inhibitor sensitivity assays, genetic epistasis (RB1/BRCA2 co-deletion models), E2F1 pathway manipulation, ATR inhibitor rescue experiments\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal genetic epistasis experiments with defined phenotypic readouts and mechanistic pathway placement in a single rigorous study\",\n      \"pmids\": [\"35179959\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In RNASEH2B-mutated patient-derived lymphoblastoid cell lines, mitochondrial morphological alterations were observed, ROS production and 8-oxoGuanine levels were increased, VDAC1 signal was elevated (suggesting mitochondrial pore formation), and elevated cytoplasmic mtDNA levels were detected compared to controls, implicating mitochondrial dysfunction and mtDNA release in AGS pathogenesis.\",\n      \"method\": \"Transmission electron microscopy, flow cytometry (ROS, mitochondrial membrane potential), Seahorse metabolic analyzer, immunofluorescence (8-oxoGuanine, VDAC1), Western blot and RT-qPCR for mtDNA release — patient LCLs vs. controls\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — multiple orthogonal methods in patient-derived cells, single lab, no genetic rescue or reconstitution to confirm RNASEH2B as direct cause\",\n      \"pmids\": [\"36430958\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"An intronic RNASEH2B variant (c.322-17 A>G) affects pre-mRNA splicing, causing 16-nucleotide intronic retention in the RNASEH2B transcript, introduction of an out-of-frame early termination codon, and reduced RNASEH2B protein expression in patient blood.\",\n      \"method\": \"RNA studies (splice analysis), exome and genome sequencing, mRNA expression quantification\",\n      \"journal\": \"European journal of medical genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct RNA splicing assay with functional consequence (reduced protein), single case/lab\",\n      \"pmids\": [\"36775013\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Novel compound heterozygous mutations in RNASEH2B reduce RNase H2B transcript and protein levels; structural analysis showed both mutations remove intramolecular contacts, destabilizing the RNase H2B subunit and the entire RNase H2 complex. Lower RNase H2A and deep depletion of RNase H2C protein levels were also observed in the affected patient, indicating interdependence of complex subunit stability.\",\n      \"method\": \"NGS sequencing, Western blot (protein quantification), RT-qPCR (transcript quantification), structural/computational modeling\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — protein/transcript quantification in patient cells plus computational structural modeling; no in vitro reconstitution or mutagenesis to validate structural predictions\",\n      \"pmids\": [\"33981319\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"An intronic RNASEH2B variant (c.65-13G>A) creates a new splice site, leading to an 11-bp extension in exon 2, causing a frameshift (p.Glu22Valfs*7) and truncation of the RNASEH2B protein.\",\n      \"method\": \"RNA analysis of splice site usage, next-generation sequencing\",\n      \"journal\": \"Annals of clinical and laboratory science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct RNA splicing assay demonstrating molecular mechanism of variant pathogenicity, single case\",\n      \"pmids\": [\"40750230\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Inducible overexpression of RNASEH2B increases levels of the active RNase H2 heterotrimer, demonstrating RNASEH2B as a rate-limiting subunit for assembly of the active complex. Despite increased heterotrimer levels, RNASEH2B overexpression is paradoxically associated with increased RNA:DNA hybrid levels under basal conditions, yet prevents further increases in RNA:DNA hybrids and reduces replication fork stalling caused by camptothecin or hydroxyurea. In the presence of oncogenic HRAS, increased RNase H2 levels limit RAS-induced replication fork stalling and cell death.\",\n      \"method\": \"Inducible overexpression system, RNA:DNA hybrid immunofluorescence (S9.6 antibody), DNA fiber assay (replication fork stalling), gene expression profiling, oncogene-induced replication stress models\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — multiple orthogonal methods in a single preprint study, not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2024.12.16.628316\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"RNASEH2B is a non-catalytic accessory subunit of the heterotrimeric RNase H2 endoribonuclease that, together with RNASEH2C, forms a B/C sub-complex serving as a nucleation site for RNASEH2A to assemble the active enzyme; its PIP-box mediates PCNA binding to recruit the complex to replication forks for ribonucleotide excision repair (RER), and its loss impairs RER, traps PARP at DNA lesions to sensitize cells to PARP inhibition, promotes replication stress, and triggers innate immune activation through accumulation of nucleic acid intermediates and mitochondrial mtDNA release.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"RNASEH2B is the non-catalytic accessory subunit of the heterotrimeric human RNase H2 endoribonuclease, functioning in ribonucleotide excision repair (RER) at sites of replication [#0, #1]. It nucleates assembly of the active enzyme: RNASEH2B and RNASEH2C form a soluble B/C sub-complex that serves as the docking site for catalytic RNASEH2A, and its PIP-box motif confers PCNA binding to the holoenzyme [#0]. RNASEH2B is rate-limiting for assembly of the active trimer, and the stability of the entire complex—including RNASEH2A and RNASEH2C protein levels—depends on intact RNASEH2B [#4, #6]. Functionally, loss of RNASEH2B impairs RER and sensitizes cells to PARP inhibition through PARP trapping, a vulnerability that can be reversed by co-deletion of the neighboring 13q14 gene RB1 via E2F1-driven BRCA2 upregulation and restored homologous recombination [#1]. Increased RNase H2 levels restrain replication fork stalling caused by camptothecin, hydroxyurea, or oncogenic HRAS, linking the complex to replication stress tolerance [#6]. RNASEH2B is a cause of Aicardi-Goutières syndrome; its disease-associated mutations act largely without abolishing catalytic activity, instead reducing protein expression and destabilizing the complex, and patient cells exhibit mitochondrial dysfunction and cytoplasmic mtDNA accumulation [#0, #2, #4].\",\n  \"teleology\": [\n    {\n      \"year\": 2008,\n      \"claim\": \"Established RNASEH2B as a structural, non-catalytic subunit that nucleates RNase H2 assembly and recruits the complex to PCNA, and showed that AGS mutations do not act by abolishing enzymatic activity—reframing how these mutations cause disease.\",\n      \"evidence\": \"Biochemical reconstitution of the human RNase H2 trimer, in vitro activity assays, PCNA binding assays, and analysis of AGS-linked mutant proteins\",\n      \"pmids\": [\"19015152\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Did not define the non-enzymatic mechanism by which RNASEH2B mutations cause disease\",\n        \"PIP-box contribution to in vivo fork recruitment not quantified\",\n        \"No structure of the assembled trimer reported in this study\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Connected patient RNASEH2B mutations to destabilization of the whole complex, showing subunit interdependence whereby loss of RNASEH2B lowers RNASEH2A and depletes RNASEH2C protein.\",\n      \"evidence\": \"NGS, Western blot and RT-qPCR quantification in patient cells with computational structural modeling of destabilizing mutations\",\n      \"pmids\": [\"33981319\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"Structural predictions not validated by in vitro reconstitution or mutagenesis\",\n        \"Single patient case\",\n        \"Functional RER consequence not directly measured\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Placed RNASEH2B loss in a cancer therapeutic context, showing impaired RER sensitizes cells to PARP inhibition via PARP trapping and mapping a resistance mechanism through co-deleted RB1 and E2F1-driven BRCA2.\",\n      \"evidence\": \"Prostate cancer loss-of-function models, PARP inhibitor sensitivity assays, RB1/BRCA2 epistasis, and ATR inhibitor rescue experiments\",\n      \"pmids\": [\"35179959\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Generality across other tumor types not established\",\n        \"Direct biochemical link between RER intermediates and PARP trapping not resolved\",\n        \"In vivo therapeutic validation limited\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Linked RNASEH2B mutation to mitochondrial dysfunction in AGS, with elevated ROS, 8-oxoGuanine, VDAC1, and cytoplasmic mtDNA implicating mtDNA release in disease pathogenesis.\",\n      \"evidence\": \"TEM, flow cytometry, Seahorse, immunofluorescence and mtDNA quantification in patient lymphoblastoid lines versus controls\",\n      \"pmids\": [\"36430958\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No genetic rescue or reconstitution to confirm RNASEH2B as direct cause\",\n        \"Causal chain from RER defect to mtDNA release not demonstrated\",\n        \"Single-lab, patient-cell observations\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined a splicing mechanism of pathogenicity, showing an intronic variant causes intron retention, premature termination, and reduced RNASEH2B protein.\",\n      \"evidence\": \"Splice analysis, exome/genome sequencing, and mRNA expression quantification in patient blood\",\n      \"pmids\": [\"36775013\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single case\",\n        \"Downstream effect on complex assembly not measured\",\n        \"No functional RER readout\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Showed RNASEH2B is rate-limiting for active heterotrimer assembly and that increased RNase H2 levels limit replication fork stalling under genotoxic and oncogenic stress.\",\n      \"evidence\": \"Inducible overexpression, S9.6 RNA:DNA hybrid immunofluorescence, DNA fiber assays, and oncogene-induced replication stress models (preprint)\",\n      \"pmids\": [\"bio_10.1101_2024.12.16.628316\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Not yet peer-reviewed\",\n        \"Paradoxical basal increase in RNA:DNA hybrids upon overexpression unexplained\",\n        \"Mechanism of fork protection beyond hybrid resolution unclear\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Extended the spectrum of splicing-based loss-of-function mechanisms, identifying a variant that creates a new splice site causing frameshift and protein truncation.\",\n      \"evidence\": \"RNA analysis of splice site usage and next-generation sequencing in a single case\",\n      \"pmids\": [\"40750230\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single case\",\n        \"Effect on complex stability and RER not directly assessed\",\n        \"No cellular phenotype reported\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How RER failure mechanistically drives innate immune activation and mtDNA release in AGS, and whether the PARP-trapping vulnerability generalizes as a therapeutic strategy, remain open.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Causal pathway from nucleic-acid intermediates to immune signaling not reconstituted\",\n        \"No structure of the AGS-mutant trimer linking destabilization to phenotype\",\n        \"Therapeutic generalizability beyond prostate cancer untested\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [0, 6]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2]}\n    ],\n    \"complexes\": [\"RNase H2\"],\n    \"partners\": [\"RNASEH2A\", \"RNASEH2C\", \"PCNA\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}